Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
The FDA granted lecanemab Breakthrough Therapy designation back in June, 2021.
Drug shows promise in clearing brain plaques believed to play a role in Alzheimer disease
Amyloid-related imaging abnormalities-edema seen on brain MRI most common adverse event in participants receiving high-dose aducanumab
In randomized, double-blind trial, no difference seen in scores for agitated behaviors at 12 weeks with mirtazapine versus placebo
By using animal images, the test avoids cultural or educational bias and can be used repeatedly with no learning effect.
Adlarity is a once-weekly transdermal formulation of donepezil.
Does not improve primary outcome, but did improve performance on certain cognitive tasks in those with epileptiform activity
Overall, 92.2, 91.0, and 85.5 percent of Medicare beneficiaries with ADRDs, Alzheimer disease, and MCI met at least one of the exclusion criteria